-
NeuShen Therapeutics Closes $20M Series Pre-A Financing for CNS Drug Development
•
NeuShen Therapeutics has announced the successful closure of a $20 million Series pre-A financing round led by Lapam Capital. The proceeds will be used to advance the company’s central nervous system (CNS) drug research and development platform, as well as to support the development of new drugs targeting CNS disorders.…
-
Zelgen Files NDA for Jacktinib to Treat Myelofibrosis in China
•
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has filed a New Drug Application (NDA) with the National Medical Products Administration (NMPA) for its JAK inhibitor, jacktinib, to treat medium to high risk myelofibrosis (MF). This includes primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (Post PV MF), and…
-
Innovent Biologics Reports 15.3% Revenue Growth in 2022 Interim Results
•
China-based Innovent Biologics, Inc. (HKG: 1801) has released its 2022 interim report, recording RMB 2.24 billion ($311.2 million) in revenue during the first half of this year, up 15.3% year-on-year (YOY). Product sales increased 10% YOY to RMB 2.04 billion ($283.4 million), driven by Tyvyt (sintilimab), a programmed death-1 (PD-1)…
-
Lepu Biotechnology’s MRG003 Receives Breakthrough Therapy Designation for Nasopharyngeal Carcinoma
•
China-based Lepu Biotechnology Co., Ltd (HKG: 2157) has announced that it has received Breakthrough Therapy Designation (BTD) from the Center for Drug Evaluation for its core product MRG003 in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC). The epidermal growth factor receptor (EGFR) targeted antibody drug conjugate (ADC) had previously obtained Orphan Drug…
-
Lepu Biotechnology’s PD-1 Inhibitor HX008 Gains New Indication Approval
•
China-based Lepu Biotechnology Co., Ltd (HKG: 2157) has announced that it has received another indication approval from the National Medical Products Administration (NMPA) for its HX008, a programmed death 1 (PD-1) targeted humanized IgG4 monoclonal antibody (mAb). The drug, which was first approved in China in July this year for…
-
Neurophth Biotechnology Doses First Patient in Phase III Trial for NR082
•
China-based gene therapy specialist Neurophth Biotechnology Ltd has announced that the first patient has been dosed in a Phase III clinical study for its NR082 (rAAV2-ND4, NFS-01). The study is being conducted in China to evaluate the efficacy and safety of NR082, a recombinant adeno-associated virus serotype 2 (rAAV2), in…
-
Bio-Thera Solutions Completes Phase I Study for COVID-19 Antibody BAT2022
•
Guangzhou-based Bio-Thera Solutions (SHA: 688177) has announced the completion of all dosage groups (from 100 mg to 1500 mg) in a Phase I clinical study for its BAT2022. The results of the study demonstrated good safety across all dosage groups. BAT2022: Drug OverviewBAT2022 is a bispecific neutralizing antibody against COVID-19…
-
Allergan Aesthetics Opens Shanghai Innovation Center for Medical Aesthetics
•
Allergan Aesthetics, a division of AbbVie, has officially opened its Shanghai innovation center, marking a significant expansion into the Chinese market. The center will focus on medical aesthetics education and product clinical application training, further solidifying Allergan Aesthetics’ commitment to advancing the field of aesthetic medicine. Center’s Focus and ObjectivesThe…
